From: Asthma–COPD overlap syndrome (ACOS) in primary care of four Latin America countries: the PUMA study
Variables | Asthma | COPD | ACOS | p-value |
---|---|---|---|---|
(N = 149) | (N = 227) | (N = 82) | ||
Pre-bronchodilator FEV1, L | 2.4 (0.6) | 1.6 (0.7) | 1.4 (0.6) | <0.001 |
Pre-bronchodilator FEV1, % pred. | 90.0 (16.3) | 62.7 (22.1) | 54.6 (21.9) | <0.001 |
Post-bronchodilator FEV1, L | 2.4 (0.6) | 1.7 (0.7) | 1.5 (0.6) | <0.001 |
Post-bronchodilator FEV1, % pre. | 92.3 (14.2) | 65.2 (20.9) | 60.7 (20.7) | <0.001 |
FEV1 change, mL (absolute) | 56.7 (173.8) | 68.1 (169.6) | 149.6 (187.8) | <0.001 |
FEV1 change, % (relative) | 3.5 (10.5) | 6.0 (13.4) | 17.9 (48.2) | <0.001 |
Pre-bronchodilator FVC, L | 3.0 (0.7) | 2.7 (0.9) | 2.4 (0.8) | <0.001 |
Pre-bronchodilator FVC, % pred. | 88.4 (15.6) | 75.7 (19.2) | 70.1 (19.1) | <0.001 |
Post-bronchodilator FVC, L | 3.0 (0.7) | 2.8 (0.9) | 2.6 (0.8) | <0.001 |
Post-bronchodilator FVC, % pred. | 89.1 (13.9) | 79.4 (18.6) | 76.6 (18.8) | <0.001 |
FVC change, mL (absolute) | 21.8 (200.5) | 139.1 (249.3) | 214.0 (207.6) | <0.001 |
FVC change, % (relative) | 1.6 (9.6) | 6.2 (11.8) | 10.3 (10.3) | <0.001 |